LNTH:NSD-Lantheus Holdings Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 94

Change

-2.92 (-3.01)%

Market Cap

USD 6.40B

Volume

0.72M

Analyst Target

USD 21.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-08 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
VTRS Viatris Inc

-0.04 (-0.33%)

USD 15.08B
NBIX Neurocrine Biosciences Inc

+1.16 (+0.84%)

USD 13.98B
ITCI Intracellular Th

-0.67 (-0.80%)

USD 8.88B
ALKS Alkermes Plc

-0.12 (-0.42%)

USD 4.70B
ALVO Alvotech

+0.15 (+1.15%)

USD 4.00B
HCM HUTCHMED DRC

+0.06 (+0.40%)

USD 2.64B
SUPN Supernus Pharmaceuticals Inc

+0.63 (+1.68%)

USD 2.05B
AMPH Amphastar P

+1.38 (+3.91%)

USD 1.75B
DVAX Dynavax Technologies Corporati..

-0.21 (-1.64%)

USD 1.71B
EVO Evotec SE ADR

-0.28 (-6.10%)

USD 1.70B

ETFs Containing LNTH

W311:F HAN-GINS Indxx Healthcare.. 4.62 % 0.00 %

N/A

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 4.62 % 0.00 %

N/A

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 4.62 % 0.00 %

N/A

N/A
MEDI Harbor Health Care ETF 3.31 % 0.00 %

-0.11 (0.12%)

USD 0.02B
GRPM Invesco S&P MidCap 400 GA.. 3.01 % 0.00 %

+0.14 (+0.12%)

N/A
WELP:LSE HAN-GINS Indxx Healthcare.. 1.39 % 0.00 %

+3.70 (+0.12%)

N/A
QWST 1.37 % 0.00 %

N/A

N/A
RTWO:LSE L&G Russell 2000 US Small.. 0.58 % 0.00 %

-0.94 (0.12%)

USD 0.23B
RTWP:LSE Legal & General UCITS ETF.. 0.58 % 0.00 %

+15.00 (+0.12%)

USD 0.23B
IWO iShares Russell 2000 Grow.. 0.00 % 0.24 %

-1.77 (0.12%)

N/A
RFG Invesco S&P MidCap 400® .. 0.00 % 0.35 %

+0.21 (+0.12%)

N/A
VRTGX Vanguard Russell 2000 Gro.. 0.00 % 0.00 %

-2.53 (0.12%)

USD 1.19B
AGED:LSE iShares Ageing Population.. 0.00 % 0.00 %

-0.05 (0.12%)

N/A
AGES:LSE iShares IV Public Limited.. 0.00 % 0.00 %

+2.63 (+0.12%)

N/A
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.00 %

-0.03 (0.12%)

N/A
ETLZ:XETRA L&G Russell 2000 US Small.. 0.00 % 0.00 %

+0.24 (+0.12%)

USD 0.09B
W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

+0.02 (+0.12%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.07% 75% C 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.07% 75% C 79% B-
Trailing 12 Months  
Capital Gain 58.54% 91% A- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 58.54% 91% A- 88% B+
Trailing 5 Years  
Capital Gain 390.35% 98% N/A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 390.35% 98% N/A 97% N/A
Average Annual (5 Year Horizon)  
Capital Gain 68.28% 87% B+ 90% A-
Dividend Return 68.28% 87% B+ 90% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 66.95% 51% F 30% F
Risk Adjusted Return 101.98% 99% N/A 97% N/A
Market Capitalization 6.40B 96% N/A 90% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.